Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21190927 | 0.90 | PTGS2 (0.42) | BRD4LRRK2GPR119PTGS2FFAR2 | |
| SCHEMBL21190908 | 0.88 | BRD4 (0.49) | BRD4LRRK2RAF1BRAFATXN2 | |
| SCHEMBL21191119 | 0.84 | BRD4 (0.49) | BRD4LRRK2RAF1BRAFTBK1 | |
| SCHEMBL21191042 | 0.84 | BRD4 (0.51) | BRD4LRRK2RAF1BRAFATXN2 | |
| SCHEMBL21190880 | 0.80 | TBK1 (0.41) | BRD4LRRK2TBK1GPR119PTGS2 | |
| SCHEMBL21191044 | 0.80 | PTGS2 (0.42) | BRD4PTGS2PTGS1 | |
| SCHEMBL18224565 | 0.80 | ALPL (0.40) | LRRK2PTGS2PTGS1 | |
| SCHEMBL21190890 | 0.78 | BRD4 (0.40) | BRD4PTGS2FFAR2PTGS1 | |
| SCHEMBL31441478 | 0.74 | LRRK2 (0.43) | LRRK2 | |
| SCHEMBL21191029 | 0.74 | BRD4 (0.47) | BRD4PTGS2PTGS1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741758-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | BRD4, BRD1, BRD3 | BRD4 1/4885LRRK2 402/4885RAF1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.